摘要
目的:探讨先期化疗对晚期卵巢癌患者癌组织、外周血及腹水中多药耐药基因MDR1表达的影响,进一步探讨癌组织、外周血及腹水三者中耐药基因表达是否具有一致性,同时评价先期化疗的临床疗效。方法:采用RT-PCR技术检测25例晚期卵巢癌患者先期化疗后癌组织、外周血及腹水中的MDR1表达情况,取同期手术的晚期卵巢癌患者31例作为对照;观察肿瘤细胞减灭术满意率及手术后CA125的下降情况。结果:先期化疗组MDR1在癌组织、外周血及腹水中表达率分别为40.0%、28.0%和32.0%;术前未化疗组MDR1表达率分别为35.5%、25.8%及29.0%,两组MDR1表达比较差异无统计学意义(P>0.05),两组组内比较差异亦无统计学意义(P>0.05);同时得出癌组织、外周血及腹水三者中耐药基因表达的一致性;先期化疗组肿瘤细胞减灭术满意率高于未化疗组,差异有统计学意义(P<0.05),先期化疗组手术后CA125水平下降明显,与未化疗组比较差异有统计学意义(P<0.05)。结论:晚期卵巢癌先期化疗后MDR1表达未见明显增高;癌组织、外周血白细胞及腹水癌细胞中MDR1表达具有一致性。先期化疗提高了晚期卵巢癌患者的肿瘤细胞减灭术满意率,加快了CA125水平的下降。
Objective：To explore the effect of primary chemotherapy on the expression levels of multidrug resistance gene 1（MDR1） in ovarian carcinoma tissues,ascites and peripheral blood of patients with advanced ovarian carcinoma,further explore there is consistency of MDR1 expression in the three samples or not,and evaluate the clinical efficacy of primary chemotherapy.Methods：RT-PCR technique was used to detect the expression levels of MDR1 in ovarian carcinoma tissues,ascites and peripheral blood of 25 patients with advanced ovarian carcinoma after primary chemotherapy;31 patients with advanced ovarian carcinoma who received operation at the same time were selected as control group.The satisfaction rate of cytoreductive surgery and the decrease situation of CA125 after surgery were observed.Results：The expression rates of MDR1 in ovarian carcinoma tissues,ascites and peripheral blood of primary chemotherapy group were 40.0%,28.0% and 32.0%,respectively;while the expression rates of MDR1 in ovarian carcinoma tissues,ascites and peripheral blood of control group were 35.5%,25.8% and 29.0%,respectively,there was no significant difference between the two groups（P0.05）,and in the two groups,there was no significant difference in expression rate of MDR1 among ovarian carcinoma tissues,ascites and peripheral blood（P0.05）;there was consistency of MDR1 expression in ovarian carcinoma tissues,ascites and peripheral blood;the satisfaction rate of cytoreductive surgery in primary chemotherapy group was significantly higher than that in control group（P0.05）;the level of CA125 after surgery in primary chemotherapy group decreased significantly,there was significant difference between primary chemotherapy group and control group（P0.05）.Conclusion：The expression of MDR1 after primary chemotherapy doesn＇t increase significantly in patients with advanced ovarian carcinoma;there is consistency of MDR1 expression in ovarian carcinoma tissues,ascites and peripheral blood.Primary chemotherapy increases the satis
出处
《中国妇幼保健》
CAS
北大核心
2011年第18期2822-2825,共4页
Maternal and Child Health Care of China
基金
河北省卫生厅医学科学研究重点课题计划〔20100132〕
关键词
卵巢癌
外周血白细胞
腹水癌细胞
MDR1
RT-PCR
先期化疗
CA125
Ovarian carcinoma
Leucocytes in peripheral blood
Cancer cells in ascites
Multidrug resistance gene 1
RT-PCR
Primary chemotherapy
CA125
